Video
Dr. Albala on financial implications of emergence of PSMA-PET imaging
Author(s):
“What’s important is that we get these studies approved so that our patients aren’t suffering any further economic burdens by having this new type of imaging being put forward,” says David Albala, MD.
Video Player is loading.
In this video, urologist David Albala, MD, explains financial issues related to the emergence of PSMA-PET imaging as a critical component of the prostate cancer management paradigm. Albala is discussing PSMA-PET imaging during the CME program at the 2022 LUGPA Annual Meeting. He is a urologist at Associated Medical Professionals in Syracuse, New York.
Related Videos
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Related Content
